2026-05-06 · 2026-05 / week-1

Kezar Is No Longer Just a Cash Tender

Kezar Is No Longer Just a Cash Tender

Summary: KZR is trading above Aurinia's $6.955 cash tender price because the market is assigning value to a nontransferable CVR. The disagreement is whether the CVR is a small biotech lottery ticket or a near-term claim on closing net cash that can be measured within months.

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 Kezar cash-plus-CVR tender cash-plus-CVR / biotech event KZR traded at $7.35 at 21:59:06 Singapore time on May 6, 2026, versus $6.955 cash plus one nontransferable CVR. The market is paying $0.395 for the CVR and closing risk two days before tender expiration. Aurinia offer documents from April 2026, Kezar 2025 10-K, live quote snapshot Tender expires one minute after 11:59 p.m. Eastern time on May 8, 2026, unless extended CVR has a near-term net-cash bucket plus longer-dated drug and asset-sale optionality Deal spread is small, CVR is nontransferable, and final net cash may land near the $50 million threshold
2 Assertio amended Garda cash tender amended tender / window-shop Garda raised the cash offer to $21.80 and removed the original CVR after a window-shop process. The stock was reported near $21.61, leaving less than 1% spread. May 4-5, 2026 company and market reports Tender commencement postponed to May 8, 2026 Cash-only close if conditions are met Spread is thin and the setup has less residual optionality
3 Arcellx cash-plus-CVR deal residue cash-plus-CVR / stale quote risk ACLX last showed $115.07 against a $115 cash deal plus CVR, but the live quote tool's last trade timestamp was April 28, 2026. Quote stale; deal materials current only through prior closing window Not reliable enough for a fresh trade note Potential CVR looks cheap if the security were still live Current tradability cannot be verified

Selected opportunity: Kezar Life Sciences common stock (KZR).

Why this one now: The tender expires on May 8. The market is no longer debating the cash price. It is underwriting a nontransferable CVR at roughly $0.395 per share.

What should surprise the reader: The first CVR bucket is not only a distant clinical milestone. It includes 100% of closing net cash above $50 million, a number Aurinia must determine not later than 90 days after closing.

Why This Is the Best Opportunity Right Now

The best mispricing today is small, mechanical, and easy to misunderstand. That is why it belongs on the desk.

Aurinia is offering $6.955 in cash for each Kezar share plus one nontransferable CVR. At $7.35, the market is paying about $0.395 above the cash consideration. That premium is not a generic merger-arbitrage spread. It is the price of the CVR, net of deal risk, timing, and tender logistics.

The market may be treating the CVR as a biotech tail. The filing says it is also a cash audit. Holders are entitled to their pro rata share of final closing net cash above $50 million. Kezar had $71.9 million of cash and cash equivalents at December 31, 2025, no marketable securities, and no debt after repaying its Oxford loan in October 2025. The company also used $51.8 million of cash in operations during 2025, so the cash bucket is not riskless. But it is not imaginary.

What Should Surprise the Reader

The CVR's cash bucket gives the trade a near-term measurement point. Most biotech CVRs depend on clinical, regulatory, or sales milestones that can take years and never pay. This CVR still has those risks, but it also has a first bucket tied to closing net cash.

The Schedule 14D-9 says the final net-cash excess over $50 million must be determined not later than 90 days after closing. That creates a measurable first payment path. If final net cash is $53 million and the share count is roughly 7.3 million, the cash-excess bucket alone would be about $0.41 per CVR before post-closing CVR-related expenses and other adjustments. At $7.35, the market is asking the buyer to pay almost exactly that amount for the entire CVR plus closing risk.

That is the disagreement. The CVR is not obviously cheap. It is also not obviously a worthless stub.

The Setup

Aurinia announced on March 30 that it would acquire Kezar through a tender offer and back-end merger. The offer price is $6.955 in cash plus one nontransferable CVR per share. The offer documents state that the tender expires one minute after 11:59 p.m. Eastern time on May 8, 2026, unless extended or terminated.

The CVR has five relevant value buckets:

CVR Bucket What Holders May Receive Timing / Condition Evidence Quality
Closing net cash 100% of final closing net cash above $50 million, pro rata Determined not later than 90 days after closing High
Zetomipzomib license or disposition 90% of net proceeds from qualifying legacy-asset transactions Within the CVR agreement period Medium
Zetomipzomib development milestones Up to $85 million of aggregate clinical, regulatory, and sales milestones if Aurinia advances the asset Long dated and conditional Low
Zetomipzomib royalties 3% of net sales if commercial sales occur Long dated and highly uncertain Low
Everest and Enodia proceeds 90% of Everest collaboration net proceeds and 100% of Enodia asset-purchase net proceeds Conditional on actual receipt Medium-low

The tender is backed by Tang Capital Partners, which holds about 9% of Kezar's outstanding shares and signed a tender and support agreement. The closing condition still requires a majority of outstanding shares to be tendered.

The Market Price

KZR traded at $7.35 at 21:59:06 Singapore time on May 6, 2026. The live quote snapshot showed a market capitalization of about $53.8 million and very light intraday volume of 411 shares.

Market Level Value Source / Timestamp Why It Matters
KZR common $7.35 Live quote snapshot, 21:59:06 Singapore time, May 6, 2026 Current combined cash-plus-CVR market price
Cash tender amount $6.955 Aurinia offer documents Fixed cash consideration if the offer closes
Implied CVR plus deal-risk premium $0.395 Desk calculation: $7.35 minus $6.955 Market price of CVR value, closing risk, and tender mechanics
December 31, 2025 cash and equivalents $71.9 million Kezar 2025 10-K Starting point for estimating final net cash
2025 operating cash burn $51.8 million Kezar 2025 10-K Burn-rate context for closing net cash risk
Final net-cash threshold $50.0 million Aurinia offer documents and Kezar Schedule 14D-9 First CVR payment starts only above this level

The live quote is thin. That is not a footnote. It means the displayed price may be a poor guide to executable size.

The Positioning

Open-source positioning data is incomplete. There is no reliable current borrow, options, or merger-arb ownership data in the sources checked for this article.

The observable positioning is implied by price. A stock trading $0.395 above fixed cash consideration two days before tender expiration is no longer being held only for cash. Holders are paying for the CVR, and any buyer today is choosing to underwrite a nontransferable instrument whose value will not be marked on an exchange after closing.

That creates a forced-choice audience. Pure cash-spread investors may avoid it because the cash price is below the market price. Biotech optionality investors may like it because the downside is anchored by cash if the offer closes. Both are partly right.

The Catalyst

The immediate catalyst is tender expiration on May 8, 2026. If the minimum tender condition and other closing conditions are satisfied, the trade should move from listed common stock to cash plus a private CVR.

The second catalyst is the final closing net-cash determination, due not later than 90 days after closing. This is the cleanest CVR measurement point.

The third catalyst is any development, license, sale, or collaboration proceeds tied to zetomipzomib, Everest, or Enodia. Those buckets are real contractual claims, but they are farther from cash and easier to overvalue.

The Gap

The market is pricing the CVR at about $0.395. That price can be defended if final closing net cash is only modestly above $50 million and the legacy-asset buckets are treated as low-probability options.

The variant view is that the first bucket is underappreciated because the CVR label makes investors think only about clinical milestones. Kezar's balance sheet gives the cash bucket enough substance to matter. Starting cash was $71.9 million at year-end. The buyer's cash consideration was negotiated around a $50 million signing net-cash threshold. If operating burn, deal fees, and wind-down costs do not consume the spread, the first CVR payment can cover much of the current premium before the clinical buckets are valued at all.

This is not a large mispricing. It is a narrow, time-sensitive one.

The Payoff Map

One possible expression is to own and tender the common only if the investor is willing to receive an illiquid CVR and can tolerate the offer failing or extending. Buying above $6.955 without intending to underwrite the CVR is incoherent.

A cleaner alternative is no trade. That is acceptable here. The expected edge is not large enough to justify sloppy tender mechanics, uncertain settlement, or size beyond the displayed liquidity.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 30% $7.95-$8.60 total value +8% to +17% from $7.35 Cash bucket within 90 days after close; longer for asset buckets Final net cash meaningfully exceeds $50 million and at least one legacy-asset bucket has credible value Medium
Base Case 45% $7.35-$7.65 total value 0% to +4% from $7.35 1-4 months for first payment Offer closes and final net cash exceeds $50 million by a modest amount Medium
Bottom Case 25% $6.70-$6.95 total value -5% to -9% from $7.35 Immediate to 2 months Tender fails, extends with adverse information, or final net cash is near the threshold and CVR is marked down Medium
Invalidation / Stop Condition n/a Price below $6.955 cash value on no new deal break, or final net-cash disclosure near $50 million Thesis break Immediate to 90 days after close Evidence that cash burn, fees, or liabilities erase the net-cash bucket High

Probability-weighted expected value: Using scenario midpoints of $8.275, $7.50, and $6.825, the probability-weighted value is about $7.56, or roughly 2.9% above the $7.35 quote. The edge is positive but small.

Current market price / level: KZR at $7.35.

Timestamp: 21:59:06 Singapore time, May 6, 2026.

Primary instrument: Kezar Life Sciences common stock (KZR).

Alternative expressions considered: Own-and-tender common for cash plus CVR; avoid the trade if CVR custody or tender mechanics are uncertain; no listed-CVR substitute exists.

Confidence: Medium. The cash bucket is measurable, but final net cash and CVR liquidity are not known today.

What Could Go Wrong

The strongest counterargument is that the market has already priced this correctly. The $0.395 premium may be a fair estimate of the cash-excess bucket after burn, fees, and expenses, with little assigned to the drug and collaboration buckets. If so, the trade is not mispriced. It is just small.

The most fragile assumption is closing net cash. Kezar had $71.9 million at year-end, but it also burned $51.8 million in operations during 2025. A reduced operating plan should lower the burn, but transaction costs, employee costs, wind-down expenses, and CVR-related deductions can still move the number.

Tender mechanics are another risk. A buyer who misses the tender deadline, cannot hold the CVR, or faces broker restrictions can own the right thesis and still get the wrong instrument.

The clinical bucket can also be a trap. Up to $85 million of milestones sounds meaningful relative to Kezar's market value, but those payments require development, regulatory, and commercial outcomes. Treating them as near-cash would be a category error.

What Would Prove This Wrong

This thesis is wrong if final closing net cash is near $50 million and the remaining CVR buckets have no near-term monetization path. It is also wrong if the tender fails or extends because the minimum tender condition is not satisfied, regulatory conditions change, or a superior bid process reopens timing risk.

The positive invalidation would be different: if a filing or credible buyer disclosure shows materially higher closing net cash, then the CVR is not merely worth $0.395. In that case, the current premium is too low, not too high.

Bottom Line

Kezar is a cash tender with a small but real CVR underwriting problem attached. At $7.35, the market is paying $0.395 above the fixed cash price for a nontransferable claim whose first bucket is final net cash above $50 million. The setup is not dramatic. It is better than dramatic: dated, measurable, and easy to misclassify. The trade is only for holders who understand tender logistics and can hold an illiquid CVR. Everyone else can still use the setup as a clean lesson in separating cash consideration from contingent value.

Research Quality Scorecard

The Research Quality Scorecard, source table copies, packaging notes, internal audit trail, and cover illustration brief are preserved in the companion meta file.

Sources